

Medical Policy: Sarclisa (isatuximab)

| POLICY NUMBER | LAST REVIEW | ORIGIN DATE |
|---------------|-----------------|--------------|
| MG.MM.PH.215 | January 8, 2024 | June 3, 2020 |

Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Sarclisa (isatuximab) is an IgG1-derived monoclonal antibody that binds to CD38 expressed on the surface of hematopoietic and tumor cells, including multiple myeloma cells. Isatuximab-irfc induces apoptosis of tumor cells and activation of immune effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC) and inhibits the ADP-ribosyl cyclase activity of CD38. Isatuximab-irfc can activate natural killer (NK) cells in the absence of the CD38-positive target tumor cells and suppresses CD38-positive T-regulatory cells. The combination of isatuximab plus pomalidomide enhanced antibody-dependent, cell-mediated cytotoxicity activity and direct tumor cell killing compared to isatuximab alone (in vitro) and enhanced antitumor activity compared to isatuximab or pomalidomide activities alone in animal models.

Length of Authorization

Coverage will be provided for 6 months and may be renewed.

Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- Cycle 1 every week x 4 doses, followed by Cycle 2, and beyond, every 2 weeks
- 110 billable units per dose

Guideline

I. INITIAL APPROVAL CRITERIA

Sarclisa may be considered medically necessary if one of the below conditions are met **AND** use is consistent with the medical necessity criteria that follows:

1. Multiple Myeloma

- A. Patient has a diagnosis of relapsed, refractory, or progressive disease; **AND**
- B. Used in combination with Pomalyst® (pomalidomide) and dexamethasone after at least two prior therapies including lenalidomide and a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib, etc.); **OR**
- C. Used in combination with carfilzomib and dexamethasone in patients who have received 1 to 3 prior lines therapy

Limitations/Exclusions

Sarclisa (Isatuximab) is not considered medically necessary for when any of the following selection criteria is met:

1. Disease progression while on Sarclisa.
2. Dosing exceeds single dose limit of 10 mg/kg body weight.
3. The patient must be 18 years of age and older
4. Indications not supported by CMS recognized Compendia or acceptable peer reviewed literature may be deemed as not approvable and therefore not reimbursable.

II. RENEWAL CRITERIA

Coverage can be renewed based upon the following criteria:

1. Patient continues to meet criteria identified in Initial Approval Criteria
2. Stabilization of disease and/or absence of progression of disease; **AND**
3. Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe infusion reactions, neutropenia, thrombocytopenia, etc.

Dosage/Administration

| Indication | Dose |
|------------------|--|
| Multiple Myeloma | Combination therapy with pomalidomide and dexamethasone OR carfilzomib and dexamethasone: 10 mg/kg of actual body weight given as an intravenous infusion: <ul style="list-style-type: none"> • Weekly Cycle 1 (four doses total; Days 1, 8, 15, & 22) • Every two weeks Cycle 2 and beyond (two doses per cycle; Days 1 & 15) <i>*Each treatment cycle consists of a 28-day period. Treatment is repeated until disease progression or unacceptable toxicity</i> |

The following medications are infused 15 to 60 minutes prior to administration of Sarclisa infusion to reduce the risk of an infusion reaction

- Dexamethasone 40 mg orally or intravenously (or 20 mg orally or intravenously for patients ≥75 years of age).
- Acetaminophen 650 mg to 1000 mg orally (or equivalent).
- H2 antagonists.

- *Diphenhydramine 25 mg to 50 mg orally or intravenously (or equivalent). The intravenous route is preferred for at least the first 4 infusions.*

Applicable Procedure Codes

| Code | Description |
|-------|---|
| J9227 | Injection, isatuximab-irfc, 10 mg (Sarclisa). J-Code effective date: 10/01/2020 |

Applicable NDCs

| Code | Description |
|---------------|---|
| 00024-0654-01 | Sarclisa 100 mg (5 ml) single use vial |
| 00024-0656-01 | Sarclisa 500 mg (25 ml) single use vial |

ICD-10 Diagnoses

| Code | Description |
|--------|--|
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma, in relapse |
| C90.10 | Plasma cell leukemia not having achieved remission |
| C90.12 | Plasma cell leukemia in relapse |
| C90.20 | Extramedullary plasmacytoma not having achieved remission |
| C90.22 | Extramedullary plasmacytoma in relapse |
| C90.30 | Solitary plasmacytoma not having achieved remission |
| C90.32 | Solitary plasmacytoma in relapse |
| Z85.79 | Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues |

Revision History

| Company(ies) | DATE | REVISION |
|-----------------------------|----------|--|
| EmblemHealth & ConnectiCare | 1/8/2024 | Annual Review: Added dosing limits, updated dosage chart |
| EmblemHealth & ConnectiCare | 5/9/2023 | Annual Review: Multiple Myeloma Initial Criteria: Removed "Patient has a diagnosis of relapsed or progressive disease." i. Used in combination with Pomalyst® (pomalidomide) and dexamethasone; AND ii. Failure of at least two prior therapies, including Revlimid® (lenalidomide) and a proteasome inhibitor (i.e. bortezomib, ixazomib, or carfilzomib)" Added "A. Patient has a diagnosis of relapsed, refractory, or progressive disease; AND B. Used in combination with Pomalyst® (pomalidomide) and dexamethasone after at least two prior therapies including lenalidomide |

| | | |
|-----------------------------|-----------|---|
| | | and a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib, etc.); OR C. Used in combination with carfilzomib and dexamethasone in patients who have received 1 to 3 prior lines therapy “ Exclusion Criteria Multiple Myeloma- Removed “Members with Known Human immunodeficiency virus (HIV) infection or active Hepatitis A, B, or C infection” |
| EmblemHealth & ConnectiCare | 1/12/2023 | Transfer to New Template |
| EmblemHealth & ConnectiCare | 9/11/2020 | Added J-Code (J9227) Injection, isatuximab-irfc, 10 mg (Sarclisa). J-Code effective date: 10/01/2020 |
| EmblemHealth & ConnectiCare | 6/3/2020 | New Policy |

References

1. Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Blood*. 2019;134(2):123–133. doi:10.1182/blood-2019-02-895193
2. Sarclisa (isatuximab) [prescribing information]. Bridgewater, NJ: Sanofi-aventis US LLC; March 2020.
3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. Multiple Myeloma. Version 3.2020. Accessed March 24, 2020.
4. National Comprehensive Cancer Network (NCCN) Compendia. Sarclisa. Accessed March, 31, 2020.
5. FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma. *FDA News Release*. March 2, 2020. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-patients-previously-treated-multiple-myeloma>.